Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres

被引:143
作者
Mentha, G [1 ]
Giostra, E
Majno, PE
Bechstein, WO
Neuhaus, P
O'Grady, J
Praseedom, RK
Burroughs, AK
Le Treut, YP
Kirkegaard, P
Rogiers, X
Ericzon, BG
Hockerstedt, K
Adam, R
Klempnauer, J
机构
[1] Univ Hosp, Dept Surg, Transplantat Unit, CH-1211 Geneva 14, Switzerland
[2] Univ Frankfurt, Frankfurt, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Kings Coll Hosp, London, England
[5] Addenbrookes Hosp, Cambridge, England
[6] Royal Free Hosp, London, England
[7] CHU Marseille, Marseille, France
[8] Univ Hosp Copenhagen, Copenhagen, Denmark
[9] Univ Krankenhaus Eppendorf, Hamburg, Germany
[10] Huddinge Univ Hosp, Huddinge, Sweden
[11] Univ Helsinki, Helsinki, Finland
[12] Hop Paul Brousse, Hepatobiliary Ctr, Paris, France
[13] Med Hochsch Hannover, Hannover, Germany
关键词
liver transplantation; Budd-Chiari; prognostic factors; recurrence; myeloproliferative disease;
D O I
10.1016/j.jhep.2005.12.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The results of liver transplantation for Budd-Chiari syndrome (BCS) are poorly known and the role and timing of the procedure are still controversial. The aim of this study was to investigate the results of transplantation for BCS, focusing on overall outcome, on prognostic factors and on the impact of the underlying disease. Methods: An enquiry on 248 patients representing 84% of the patients transplanted for BCS in the European Liver Transplantation Registry between 1988 and 1999. Results: Of the 248 patients, 70.4% were female and 29.6% male. The mean age was 35.7 years. The overall actuarial survival was 76% at I year, 71% at 5 years and 68% at 10 years. 77% of deaths occurred in the first 3 months: 47% were due to infection and multiple organ failure, and 18% to graft failure or hepatic artery thrombosis. Late mortality (> 1 year) occurred in nine patients, due to BCS recurrence in four of them. The only pre-transplant predictors of mortality on multivariate analysis (Cox) were impaired renal function and a history of a shunt. Conclusions: Liver transplantation for BCS is an effective treatment, irrespective of the underlying cause, and should be considered before renal failure occurs. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V.. All rights reserved.
引用
收藏
页码:520 / 528
页数:9
相关论文
共 30 条
[1]   Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study [J].
Adam, R ;
Cailliez, V ;
Majno, P ;
Karam, V ;
McMaster, P ;
Calne, RY ;
O'Grady, J ;
Pichlmayr, R ;
Neuhaus, P ;
Otte, JB ;
Hoeckerstedt, K ;
Bismuth, H .
LANCET, 2000, 356 (9230) :621-627
[2]   Treatment of Budd-Chiari syndrome in a Liver Transplant Unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation [J].
Attwell, A ;
Ludkowski, M ;
Nash, R ;
Kugelmas, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (08) :867-873
[3]   PORTASYSTEMIC SHUNTING VERSUS LIVER-TRANSPLANTATION FOR THE BUDD-CHIARI SYNDROME [J].
BISMUTH, H ;
SHERLOCK, DJ .
ANNALS OF SURGERY, 1991, 214 (05) :581-589
[4]  
CAMPBELL DA, 1988, SURG GYNECOL OBSTET, V166, P511
[5]   MULTIVARIATE SURVIVAL ANALYSIS USING COX REGRESSION-MODEL [J].
CHRISTENSEN, E .
HEPATOLOGY, 1987, 7 (06) :1346-1358
[6]  
GALATI JS, 1993, GASTROENTEROLOGY, V104, pA904
[7]   Budd-Chiaria syndrome in patients with hematological disease:: A therapeutic challenge [J].
Ganguli, SC ;
Ramzan, NN ;
McKusick, MA ;
Andrews, JC ;
Phyliky, RL ;
Kamath, PS .
HEPATOLOGY, 1998, 27 (04) :1157-1161
[8]  
GOLDSTEIN R, 1991, TRANSPLANT P, V23, P1559
[9]   LIVER-TRANSPLANTATION FOR THE BUDD-CHIARI SYNDROME [J].
HALFF, G ;
TODO, S ;
TZAKIS, AG ;
GORDON, RD ;
STARZL, TE .
ANNALS OF SURGERY, 1990, 211 (01) :43-49
[10]   PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome [J].
Hernández-Guerra, M ;
Turnes, J ;
Rubinstein, P ;
Olliff, S ;
Elias, E ;
Bosch, J ;
García-Pagán, JC .
HEPATOLOGY, 2004, 40 (05) :1197-1202